ZBH Stock Gains From Receiving CE Mark for Persona Revision Knee System

Zacks11-20

Zimmer Biomet Holdings, Inc. ZBH recently received a CE Mark for its Persona Revision Knee System. This latest development expands the Persona Knee System portfolio and supports Zimmer Biomet's ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484146571?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2zpBip7dfc108UBup7QGiw--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/28fc1568786cf7bd1a1b4ba4d8d32823","is_english":true,"pubTime":"2024-11-20 20:16","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2484146571","market":"us","top_or_hot":-1,"title":"ZBH Stock Gains From Receiving CE Mark for Persona Revision Knee System","media":"Zacks","content":"<div>\n<p>Zimmer Biomet Holdings, Inc. ZBH recently received a CE Mark for its Persona Revision Knee System. This latest development expands the Persona Knee System portfolio and supports Zimmer Biomet's ...</p>\n\n<a href=\"https://finance.yahoo.com/news/zbh-stock-gains-receiving-ce-121600826.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ZBH Stock Gains From Receiving CE Mark for Persona Revision Knee System</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZBH Stock Gains From Receiving CE Mark for Persona Revision Knee System\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 20:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/zbh-stock-gains-receiving-ce-121600826.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zimmer Biomet Holdings, Inc. ZBH recently received a CE Mark for its Persona Revision Knee System. This latest development expands the Persona Knee System portfolio and supports Zimmer Biomet's ...</p>\n\n<a href=\"https://finance.yahoo.com/news/zbh-stock-gains-receiving-ce-121600826.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4504","symbol_name":"桥水持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/zbh-stock-gains-receiving-ce-121600826.html","article_id":"2484146571","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2zpBip7dfc108UBup7QGiw--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/28fc1568786cf7bd1a1b4ba4d8d32823"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484146571","pubTimestamp":1732104960,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Zimmer Biomet Holdings, Inc. ZBH recently received a CE Mark for its Persona Revision Knee System. This latest development expands the Persona Knee System portfolio and supports Zimmer Biomet's commitment to personalized solutions.After the successful introduction of Persona Revision Knee in the United States and other markets, the latest CE Mark Certification aims to provide surgeons with advanced tools for revision knee arthroplasty globally.Following the announcement, shares of ZBH moved north 0.4% to $113.02 on Monday. The company is gaining a high level of synergies from its continued focus on Persona revision. This provides a meaningful conversion and mix opportunities in the revision category. Zimmer Biomet anticipates working on the overall shift of the company’s legacy knee systems to a fully rounded-out Persona portfolio. Thus, the latest CE Mark for the Persona Revision Knee System is in line with the company’s mission. Accordingly, we expect market sentiment to remain posit","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4504":"桥水持仓","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4548":"巴美列捷福持仓","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","CE":"塞拉尼斯","ZBH":"齐默巴奥米特控股","BK4109":"特种化学制品","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","GMED":"Globus Medical Inc","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","RMD":"瑞思迈","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","BK4567":"ESG概念","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","BK4566":"资本集团","HAE":"美国血液技术","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4082":"医疗保健设备","RMD.AU":"Resmed DRC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4588":"碎股","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","BK4198":"医疗保健用品","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC"},"translate_title":"ZBH股票因Persona翻修膝关节系统获得CE标志而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBH":1,"RMD":1,"CE":1,"GMED":1,"RMD.AU":0.9,"HAE":0.9},"content_text":"Zimmer Biomet Holdings, Inc. ZBH recently received a CE Mark for its Persona Revision Knee System. This latest development expands the Persona Knee System portfolio and supports Zimmer Biomet's commitment to personalized solutions. \nAfter the successful introduction of Persona Revision Knee in the United States and other markets, the latest CE Mark Certification aims to provide surgeons with advanced tools for revision knee arthroplasty globally. \nZBH’s Likely Stock Trend Following the News\nFollowing the announcement, shares of ZBH moved north 0.4% to $113.02 on Monday.  The company is gaining a high level of synergies from its continued focus on Persona revision. This provides a meaningful conversion and mix opportunities in the revision category. Zimmer Biomet anticipates working on the overall shift of the company’s legacy knee systems to a fully rounded-out Persona portfolio. Thus, the latest CE Mark for the Persona Revision Knee System is in line with the company’s mission. Accordingly, we expect market sentiment to remain positive for ZBH stock surrounding the announcement.\nZBH currently has a market capitalization of $22.09 billion. It’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 1.76%.\nAbout ZBH’s Persona Revision\nZimmer Biomet’s Persona Revision Knee offers a personalized fit and optimized function for patients undergoing revision knee surgery. The system's anatomic components and intuitive instrumentation reduce complexity while improving precision. The system allows for intraoperative flexibility, so surgeons can make intraoperative adjustments to achieve optimal alignment and fit for each patient.\nThe system features the company’s proprietary Trabecular Metal Technology, which promotes long-term bone in-growth and improves implant fixation. The Persona Revision Knee system is the leading product in the U.S. knee revision market.\nIndustry Prospect Favors Zimmer Biomet\nPer a Future Market Insights report, the revision knee replacement market is estimated to reach $2.00 billion by 2032 at a compound annual growth rate of 4.1% during 2022-2032. The key factor influencing the market growth is the increasing rate of old age diseases like obesity, arthritis, sports-related injuries, osteoporosis and diabetes. Moreover, technological advancements, such as minimally invasive surgery and better implant materials, are expected to drive market demand globally. \nImage Source: Zacks Investment Research\nOther Recent Developments by ZBH\nThe previous month, the company announced plans for the commercial launch of the Z1 Femoral Hip System (Z1 System) for total hip arthroplasty at the 2024 annual American Association of Hip and Knee Surgeons (AAHKS) meeting. Z1 Femoral Hip System is a triple-taper femoral system that pairs with the company's industry-leading G7 Acetabular System to provide surgeons with a versatile, streamlined and efficient total hip arthroplasty solution. \nZBH’s Price Performance\nIn the past year, shares of ZBH have declined 1.8% against the industry’s 21.2% growth. \nZBH’s Zacks Rank and Key Picks\nZBH currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Haemonetics HAE, Globus Medical GMED and ResMed RMD. While ResMed sports a Zacks Rank #1 (Strong Buy) at present, Haemonetics and Globus Medical carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.\nHaemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. Its shares have risen 1.8% compared with the industry’s 23.1% growth in the past year. Estimates for Haemonetics’ 2025 EPS have moved north 0.4% to $4.59 in the past 30 days. \nEstimates for Globus Medical’s 2024 EPS have remained constant at $2.84 in the past 30 days. Shares of the company have surged 60.6% in the past year compared with the industry’s growth of 32.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 12.1%. In the last reported quarter, it delivered an earnings surprise of 10.3%.\nEstimates for ResMed’s fiscal 2025 EPS have risen 2.7% in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 32.1% growth. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 6.4%. In the last reported quarter, it delivered an earnings surprise of 8.4%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nResMed Inc. (RMD) : Free Stock Analysis Report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nGlobus Medical, Inc. (GMED) : Free Stock Analysis Report\nZimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484146571"}